Development and validation of new self-administered questionnaire regarding the quality of life (QOL) of continuous subcutaneous insulin infusion (CSII)

Development and validation of new self-administered questionnaire regarding the quality of life (QOL) of continuous subcutaneous insulin infusion (CSII) - Development and validation of new self-administered questionnaire regarding the quality of life (QOL) of continuous subcutaneous insulin infusion (CSII) (CSII-QOL study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031595

Enrollment

Registered

2018-03-06

Start date

2018-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Type 1 diabetes. (2) Patients using insulin pump for no less than one year. (3) Patients who regularly visit or being hospitalized at the medical institute participating this study.

Exclusion criteria

Exclusion criteria: (1) Type 2 diabetes. (2) Patients who are not suitable to participate in this study for any other reasons.

Design outcomes

Primary

Measure	Time frame
Validity and reliability of new self-administered questionnaire regarding the quality of life (QOL) of continuous subcutaneous insulin infusion (CSII)	—

Secondary

Measure	Time frame
Relationship between CSII-QOL score and baseline measurements {HbA1c, age, sex, BMI, present history (diabetes duration, history of insulin therapy, history of CSII), type of insulin pump, insulin dosage (total daily dose, total basal dose), diabetic retinopathy, diabetic nephropathy, QOL (Problem Areas in Diabetes: PAID)}.	—

Countries

Japan

Contacts

Public ContactTakashi Murata

NHO Kyoto Medical Center Diabetes Center

murata-tky@umin.net075-641-9161

Outcome results